J Korean Med Assoc.  2008 Mar;51(3):273-282.

Pharmacological Therapy of Prozac

• Lyoo IK
• Lee JY
• Lee JH

Abstract

Fluoxetine (Prozac(R)) has been reported to have equivalent efficacy and less side effects compared to the tricyclic antidepressants. It has become a new trend in the treatment of major depressive disorder since 1980's. Efficacy of fluoxetine has been shown not only in major depressive disorder, but also in obsessive compulsive disorder, panic disorder, bulimia nervosa, premenstrual dysphoric disorder, obesity, premature ejaculation, pain syndrome and other medical/psychiatric diseases. Fluoxetine is known to have more activating or stimulating effect than other selective serotonin reuptake inhibitors, which might be beneficial in treating the atypical feature of depression. It is also effective in diminishing appetite and carbohydrate craving. However, this effect is belived to be transient. Regarding the adverse effects, fluoxetine has the lower risk of discontinuation syndrome in comparison with other antidepressants, due to its long halflife. However, long half-life can be problematic when adverse effects become intolerable. Caution should be made when there is a possibility of drug interaction especially in the elderly. When it is prescribed to children and adolescents, monitoring for suicidal intent should be made.

Keyword

Fluoxetine; Prozac(R); Selective serotonin reuptake inhibitor; Major depressive disorder; Antidepressant

MeSH Terms

Adolescent
Aged
Antidepressive Agents
Antidepressive Agents, Tricyclic
Appetite
Bulimia Nervosa
Child
Depression
Depressive Disorder, Major
Drug Interactions
Fluoxetine
Half-Life
Humans
Obesity
Obsessive-Compulsive Disorder
Panic Disorder
Premature Ejaculation
Serotonin Uptake Inhibitors
Antidepressive Agents
Antidepressive Agents, Tricyclic
Fluoxetine
Serotonin Uptake Inhibitors

Reference

1. Kelsey JE. Sadock BJ, Sadock VA, editors. Selective Serotonin Reuptake Inhibitor. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 2005. 8th ed. Philadelphia: Lippincott Williams & Wilkins;2887–2914.

2. Rosenbaum JF, Tollefson GD. Schatzberg AF, Nemeroff CB, editors. Fluoxetine. Essentials of Clinical Psychopharmacology. 2006. 2nd ed. Washington: American Psychiatric Publishing, Inc.;31–46.

3. Stokes PE, Holtz A. Fluoxetine Tenth Anniversary Update: The Progress Continues. Clin Ther. 1997. 19:1135–1250.

4. Davis LL, Frazier EC, Williford RB, Newell JM. Long-Term Pharmacotherapy for Post-Traumatic Stress Disorder. CNS Drugs. 2006. 20:465–476.

5. Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in Bipolar Disorder: the Case for Caution. Bipolar Disord. 2003. 5:421–433.